Skip to Content

AIM ImmunoTech Inc AIM

Morningstar Rating
$0.40 0.00 (0.10%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AIM is trading at a 62% discount.
Price
$0.40
Fair Value
$3.61
Uncertainty
Extreme
1-Star Price
$3.48
5-Star Price
$7.69
Economic Moat
Wzj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AIM is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.40
Day Range
$0.390.41
52-Week Range
$0.380.75
Bid/Ask
$0.39 / $0.40
Market Cap
$19.57 Mil
Volume/Avg
70,611 / 139,932

Key Statistics

Price/Earnings (Normalized)
Price/Sales
100.43
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
24

Valuation

Metric
AIM
Price/Earnings (Normalized)
Price/Book Value
0.89
Price/Sales
100.43
Price/Cash Flow
Price/Earnings
AIM

Financial Strength

Metric
AIM
Quick Ratio
4.77
Current Ratio
4.82
Interest Coverage
Quick Ratio
AIM

Profitability

Metric
AIM
Return on Assets (Normalized)
−54.76%
Return on Equity (Normalized)
−61.48%
Return on Invested Capital (Normalized)
−62.10%
Return on Assets
AIM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVbb$550.4 Bil
VRTX
Vertex Pharmaceuticals IncRdlmq$111.8 Bil
REGN
Regeneron Pharmaceuticals IncByvjyzy$107.9 Bil
MRNA
Moderna IncGqk$36.3 Bil
ARGX
argenx SE ADRXzm$23.0 Bil
BNTX
BioNTech SE ADRWhvv$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncXsrxmnt$19.2 Bil
BMRN
Biomarin Pharmaceutical IncYqhtkb$16.4 Bil
RPRX
Royalty Pharma PLC Class AZxlwwt$13.4 Bil
INCY
Incyte CorpHdvfd$13.3 Bil

Sponsor Center